Ibex Investors’s Fate Therapeutics FATE Stock Holding History

Ibex Investors’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-18,000	Closed	-$231K	–	85
2018 Q4	$231K	Buy	+18,000	New	+$251K	0.04%	71

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Ibex Investors's FATE Position: Q1 2019 in Review

Ibex Investors sold out of Fate Therapeutics (FATE) in Q1 2019, closing a stake of 18,000 shares — an estimated $231K sold.

Ibex Investors first reported a position in FATE in Q4 2018 and held it in 1 quarter. The position peaked at $231K in Q4 2018. 123 funds tracked by Wall St. Rank hold FATE as of Q1 2019.

Ibex Investors reported no remaining Fate Therapeutics position as of Q1 2019 after selling out during the quarter.
Ibex Investors sold 18,000 Fate Therapeutics shares in Q1 2019, an estimated $231K.
Ibex Investors first reported a position in Fate Therapeutics in Q4 2018 and held it in 1 quarter.
Ibex Investors's Fate Therapeutics position peaked at $231K in Q4 2018.
123 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2019.

Based on Ibex Investors's 13F filing for Q1 2019, filed 7 May 2019.